NCT04485013 2026-02-18TTX-080 HLA-G Antagonist in Subjects With Advanced CancersTizona Therapeutics, IncPhase 1 Recruiting240 enrolled
NCT04682431 2024-03-22A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsIkena OncologyPhase 1 Terminated127 enrolled
NCT04691375 2024-03-22A Study of PY314 in Subjects With Advanced Solid TumorsIkena OncologyPhase 1 Terminated86 enrolled
NCT04452214 2023-07-14A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCantargia ABPhase 1 Completed19 enrolled